Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
CONGESTIVE heart failure is a major and growing public health problem. About 2 million patients have congestive heart failure in the United States, and the number is expected to increase substantially in the next few decades. 1 The one-year mortality ranges from 15 percent among relatively unselecte...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 1991-08, Vol.325 (5), p.293-302 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 302 |
---|---|
container_issue | 5 |
container_start_page | 293 |
container_title | The New England journal of medicine |
container_volume | 325 |
creator | Yusuf, Salim Pitt, Bertram Davis, Clarence E Hood, William B Cohn, Jay N |
description | CONGESTIVE heart failure is a major and growing public health problem. About 2 million patients have congestive heart failure in the United States, and the number is expected to increase substantially in the next few decades.
1
The one-year mortality ranges from 15 percent among relatively unselected patients
2
to 50 percent among those in New York Heart Association functional class IV.
3
About 35 percent of all patients with a diagnosis of congestive heart failure are hospitalized every year (unpublished data).
The Veterans Administration Cooperative Vasodilator Heart Failure Trial
4
reported a lower mortality in patients with congestive heart failure treated with hydralazine . . . |
doi_str_mv | 10.1056/NEJM199108013250501 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80636952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2836234</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-a822758183104508f8f4f2665e24b7d985bfdcf2fa0e48bdcb66f0f416a1fcf63</originalsourceid><addsrcrecordid>eNp9kVuP0zAQhS0EWkrhFyAkCxAvKDC-xn5EVcqCykXcXiPHscGVk-zaSdH-e7y02gcE-MWW55szR3MQekjgBQEhX75v3r4jWhNQQBgVIIDcQisiGKs4B3kbrQCoqnit2V10L-c9lEO4PkNnFEQNjK_QVeO9szOePG5GE81FChFPI_68pEM4mIjDiD-aObhxzvhnmH_gT65frOvxzvkZfyv_KdglmoSbfREKpXebzO9Hxmbs8WYav7s8h4PD586kGW9NiEty99Edb2J2D073Gn3dNl8259Xuw-s3m1e7ygoi5sooSmuhiGIEuADlleeeSikc5V3dayU631tPvQHHVdfbTkoPnhNpiLdesjV6dtS9SNPlUpy0Q8jWxWhGNy25VSCZ1IIW8PEf4H5aUllKbillWpC6mFijJ_-CiFaMs7omulDsSNk05Zycb8teB5OuWgLtdXbtX7IrXY9O2ks3uP6m5xRWqT891U22JvpkRhvyDca1LA6uLT4_YsOQ29Hth_8O_QWza6xh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983437719</pqid></control><display><type>article</type><title>Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Yusuf, Salim ; Pitt, Bertram ; Davis, Clarence E ; Hood, William B ; Cohn, Jay N</creator><creatorcontrib>Yusuf, Salim ; Pitt, Bertram ; Davis, Clarence E ; Hood, William B ; Cohn, Jay N ; The SOLVD Investigators ; SOLVD Investigators ; The SOLVD Investigators</creatorcontrib><description>CONGESTIVE heart failure is a major and growing public health problem. About 2 million patients have congestive heart failure in the United States, and the number is expected to increase substantially in the next few decades.
1
The one-year mortality ranges from 15 percent among relatively unselected patients
2
to 50 percent among those in New York Heart Association functional class IV.
3
About 35 percent of all patients with a diagnosis of congestive heart failure are hospitalized every year (unpublished data).
The Veterans Administration Cooperative Vasodilator Heart Failure Trial
4
reported a lower mortality in patients with congestive heart failure treated with hydralazine . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199108013250501</identifier><identifier>PMID: 2057034</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Angina pectoris ; Angiotensin-converting enzyme inhibitors ; Arrhythmia ; Biological and medical sciences ; Blood Pressure - drug effects ; Cardiovascular system ; Cause of Death ; Chronic Disease ; Clinical trials ; Congestive heart failure ; Double-Blind Method ; Drug therapy ; Electrolytes - blood ; Enalapril - adverse effects ; Enalapril - therapeutic use ; Enzymes ; Female ; Follow-Up Studies ; Heart attacks ; Heart failure ; Heart Failure - drug therapy ; Heart Failure - mortality ; Heart Failure - physiopathology ; Hospitalization ; Humans ; Hypotheses ; Kidney - drug effects ; Male ; Medical sciences ; Middle Aged ; Mortality ; Patient Compliance ; Pharmacology. Drug treatments ; Stroke Volume ; Survival Rate ; Vasodilator agents. Cerebral vasodilators ; Ventricle</subject><ispartof>The New England journal of medicine, 1991-08, Vol.325 (5), p.293-302</ispartof><rights>1992 INIST-CNRS</rights><rights>Copyright Massachusetts Medical Society Aug 1, 1991</rights><rights>Copyright Massachusetts Medical Society, Publishing Division Aug 1, 1991</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-a822758183104508f8f4f2665e24b7d985bfdcf2fa0e48bdcb66f0f416a1fcf63</citedby><cites>FETCH-LOGICAL-c515t-a822758183104508f8f4f2665e24b7d985bfdcf2fa0e48bdcb66f0f416a1fcf63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199108013250501$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1983437719?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,778,782,2748,2749,26086,27907,27908,52365,54047,64366,64368,64370,72220</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4969838$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2057034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yusuf, Salim</creatorcontrib><creatorcontrib>Pitt, Bertram</creatorcontrib><creatorcontrib>Davis, Clarence E</creatorcontrib><creatorcontrib>Hood, William B</creatorcontrib><creatorcontrib>Cohn, Jay N</creatorcontrib><creatorcontrib>The SOLVD Investigators</creatorcontrib><creatorcontrib>SOLVD Investigators</creatorcontrib><creatorcontrib>The SOLVD Investigators</creatorcontrib><title>Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>CONGESTIVE heart failure is a major and growing public health problem. About 2 million patients have congestive heart failure in the United States, and the number is expected to increase substantially in the next few decades.
1
The one-year mortality ranges from 15 percent among relatively unselected patients
2
to 50 percent among those in New York Heart Association functional class IV.
3
About 35 percent of all patients with a diagnosis of congestive heart failure are hospitalized every year (unpublished data).
The Veterans Administration Cooperative Vasodilator Heart Failure Trial
4
reported a lower mortality in patients with congestive heart failure treated with hydralazine . . .</description><subject>Angina pectoris</subject><subject>Angiotensin-converting enzyme inhibitors</subject><subject>Arrhythmia</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiovascular system</subject><subject>Cause of Death</subject><subject>Chronic Disease</subject><subject>Clinical trials</subject><subject>Congestive heart failure</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Electrolytes - blood</subject><subject>Enalapril - adverse effects</subject><subject>Enalapril - therapeutic use</subject><subject>Enzymes</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - mortality</subject><subject>Heart Failure - physiopathology</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Kidney - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Patient Compliance</subject><subject>Pharmacology. Drug treatments</subject><subject>Stroke Volume</subject><subject>Survival Rate</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><subject>Ventricle</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kVuP0zAQhS0EWkrhFyAkCxAvKDC-xn5EVcqCykXcXiPHscGVk-zaSdH-e7y02gcE-MWW55szR3MQekjgBQEhX75v3r4jWhNQQBgVIIDcQisiGKs4B3kbrQCoqnit2V10L-c9lEO4PkNnFEQNjK_QVeO9szOePG5GE81FChFPI_68pEM4mIjDiD-aObhxzvhnmH_gT65frOvxzvkZfyv_KdglmoSbfREKpXebzO9Hxmbs8WYav7s8h4PD586kGW9NiEty99Edb2J2D073Gn3dNl8259Xuw-s3m1e7ygoi5sooSmuhiGIEuADlleeeSikc5V3dayU631tPvQHHVdfbTkoPnhNpiLdesjV6dtS9SNPlUpy0Q8jWxWhGNy25VSCZ1IIW8PEf4H5aUllKbillWpC6mFijJ_-CiFaMs7omulDsSNk05Zycb8teB5OuWgLtdXbtX7IrXY9O2ks3uP6m5xRWqT891U22JvpkRhvyDca1LA6uLT4_YsOQ29Hth_8O_QWza6xh</recordid><startdate>19910801</startdate><enddate>19910801</enddate><creator>Yusuf, Salim</creator><creator>Pitt, Bertram</creator><creator>Davis, Clarence E</creator><creator>Hood, William B</creator><creator>Cohn, Jay N</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19910801</creationdate><title>Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure</title><author>Yusuf, Salim ; Pitt, Bertram ; Davis, Clarence E ; Hood, William B ; Cohn, Jay N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-a822758183104508f8f4f2665e24b7d985bfdcf2fa0e48bdcb66f0f416a1fcf63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Angina pectoris</topic><topic>Angiotensin-converting enzyme inhibitors</topic><topic>Arrhythmia</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiovascular system</topic><topic>Cause of Death</topic><topic>Chronic Disease</topic><topic>Clinical trials</topic><topic>Congestive heart failure</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Electrolytes - blood</topic><topic>Enalapril - adverse effects</topic><topic>Enalapril - therapeutic use</topic><topic>Enzymes</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - mortality</topic><topic>Heart Failure - physiopathology</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Kidney - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Patient Compliance</topic><topic>Pharmacology. Drug treatments</topic><topic>Stroke Volume</topic><topic>Survival Rate</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><topic>Ventricle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yusuf, Salim</creatorcontrib><creatorcontrib>Pitt, Bertram</creatorcontrib><creatorcontrib>Davis, Clarence E</creatorcontrib><creatorcontrib>Hood, William B</creatorcontrib><creatorcontrib>Cohn, Jay N</creatorcontrib><creatorcontrib>The SOLVD Investigators</creatorcontrib><creatorcontrib>SOLVD Investigators</creatorcontrib><creatorcontrib>The SOLVD Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yusuf, Salim</au><au>Pitt, Bertram</au><au>Davis, Clarence E</au><au>Hood, William B</au><au>Cohn, Jay N</au><aucorp>The SOLVD Investigators</aucorp><aucorp>SOLVD Investigators</aucorp><aucorp>The SOLVD Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1991-08-01</date><risdate>1991</risdate><volume>325</volume><issue>5</issue><spage>293</spage><epage>302</epage><pages>293-302</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>CONGESTIVE heart failure is a major and growing public health problem. About 2 million patients have congestive heart failure in the United States, and the number is expected to increase substantially in the next few decades.
1
The one-year mortality ranges from 15 percent among relatively unselected patients
2
to 50 percent among those in New York Heart Association functional class IV.
3
About 35 percent of all patients with a diagnosis of congestive heart failure are hospitalized every year (unpublished data).
The Veterans Administration Cooperative Vasodilator Heart Failure Trial
4
reported a lower mortality in patients with congestive heart failure treated with hydralazine . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>2057034</pmid><doi>10.1056/NEJM199108013250501</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-4793 |
ispartof | The New England journal of medicine, 1991-08, Vol.325 (5), p.293-302 |
issn | 0028-4793 1533-4406 |
language | eng |
recordid | cdi_proquest_miscellaneous_80636952 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
subjects | Angina pectoris Angiotensin-converting enzyme inhibitors Arrhythmia Biological and medical sciences Blood Pressure - drug effects Cardiovascular system Cause of Death Chronic Disease Clinical trials Congestive heart failure Double-Blind Method Drug therapy Electrolytes - blood Enalapril - adverse effects Enalapril - therapeutic use Enzymes Female Follow-Up Studies Heart attacks Heart failure Heart Failure - drug therapy Heart Failure - mortality Heart Failure - physiopathology Hospitalization Humans Hypotheses Kidney - drug effects Male Medical sciences Middle Aged Mortality Patient Compliance Pharmacology. Drug treatments Stroke Volume Survival Rate Vasodilator agents. Cerebral vasodilators Ventricle |
title | Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T02%3A37%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Enalapril%20on%20Survival%20in%20Patients%20with%20Reduced%20Left%20Ventricular%20Ejection%20Fractions%20and%20Congestive%20Heart%20Failure&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Yusuf,%20Salim&rft.aucorp=The%20SOLVD%20Investigators&rft.date=1991-08-01&rft.volume=325&rft.issue=5&rft.spage=293&rft.epage=302&rft.pages=293-302&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199108013250501&rft_dat=%3Cproquest_cross%3E2836234%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983437719&rft_id=info:pmid/2057034&rfr_iscdi=true |